Engimmune Therapeutics

Last week, our CEO Lars Nieba and CSO Rodrigo Vazquez-Lombardi had a conversation with Handelsblatt about how Engimmune’s soluble TCR drug candidates redirect the immune system against solid tumours.   They also discussed how coupling advanced protein engineering methods with AI helps us identify extremely rare drug candidates that are both potent and safe. By leveraging these technologies, we continue with our mission to develop effective targeted immunotherapies to help patients suffering from cancers for which limited treatment options exist.   Video (English), Article (German). Published Friday May 31, 2024. https://lnkd.in/ekdX4cRZ

🧬 👨🔬 Spring of Science at Engimmune 👩🔬 🧪   We very much look forward to presenting a number of talks on Engimmune’s approach to AI-driven development of specificity- and affinity-enhanced soluble T cell receptors (specTRs) targeting oncology indications of high unmet medical need.   Our colleagues Sébastien Lalevée (Principal Scientist), Rodrigo Vazquez-Lombardi (CSO), Lars Nieba (CEO) and Kenneth Crook (Head of Translational Medicine) will be presenting at the Immuno-oncology Summit Europe (London, 24 April), TCR-based Therapies for Solid Tumours Summit (Boston, 25 April), Nexus Drug Discovery Conference (Basel, 25 April) and Immuno 2024 (London, 26 April), respectively. Make sure to reach out to our team members at these events or online to learn more about our innovative technologies and advancing pipeline.   Safe travels to Seb, Roddy and Ken! And a pleasant commute for Lars! https://lnkd.in/dgE7-xS https://lnkd.in/gF2zkg8 https://lnkd.in/ebgYvmRm https://lnkd.in/dCeaHGqC

Our Head of Translational Medicine Kenneth Crook will be presenting Engimmune's AI-guided platform technologies for soluble TCR drug development at Immuno 2024 on April 25-26. In this video, we get his perspective on current trends in immuno-oncology and on how specTR molecules (specificity- and affinity-enhanced soluble TCR engagers) can address key challenges in the treatment of solid tumours. https://lnkd.in/eP7XteCS

Yesterday, our CEO Dr. Lars Nieba presented Engimmune’s AI-guided technologies and soluble TCR drug pipeline at the Pitch&Connect event at our very own home Switzerland Innovation Park Basel Area. Thank you SIP for the wonderful event and to all of you that attended for the great questions and discussions! Stay tuned for more developments!

Yesterday, our CEO Dr. Lars Nieba presented Engimmune’s AI-guided technologies and soluble TCR drug pipeline at the Pitch&Connect event at our very own home Switzerland Innovation Park Basel Area. Thank you SIP for the wonderful event and to all of you that attended for the great questions and discussions! Stay tuned for more developments!

Great to see our CEO Lars Nieba quoted in Labiotech.eu talking about the future of cancer care, including the huge potential of T-cell receptor (TCR) based therapies. Engimmune Therapeutics is at the forefront of developing soluble TCRs. “These tumor-infiltrating drugs will be of particular help in tackling advanced cancers, where tumors are bigger and more developed,” said Nieba. Read the full article here: https://lnkd.in/deaSPBAB

What does the future of cancer treatment look like in 2034? 🔮 As we observe 🎗️ World Cancer Day today, we take a look at the different kinds of treatments and ongoing research that are poised to make a difference ten years down the line. 📅 From immunotherapy to precision medicine to cancer vaccines 💉, there is hope that cancer care will change for the better, although making the process for receiving treatment more affordable needs to be addressed. 💵 Labiotech spoke to experts like John Maher, CSO of Leucid Bio, Germo Gericke, CMO of Ariceum Therapeutics, Catherine Pickering, CEO of iOnctura, Lars Nieba, CEO of Engimmune Therapeutics, Liam Tremble, Principal Scientist at Poolbeg Pharma plc, and Jason Loveridge, CEO of 4SC AG, to find out more about what the future of cancer care holds in store. Read our latest article to find out! 👇 https://lnkd.in/deaSPBAB #cancerresearch #futureofcancertreatment #worldcancerday #immunotherapyadvancements #precisionmedicine #cancervaccines #affordabletreatment #medicalinnovation #expertinsights 

🗓Mark your calendars for our first "Pitch & Connect" session of 2024! Join us on Thursday, February 8, 2024, as we highlight two successful innovators at our Switzerland Innovation Park Basel Area Main Campus site in Allschwil! Epicelya Therapeutics CEO Dr. Jürg Stebler will introduce us to their innovative mRNA-technology platforms for cancer and other diseases. Their approach utilizes precision epigenetics and a novel nuclease technology platform to address unmet medical needs. Engimmune Therapeutics CEO Dr. Lars Nieba will present Engimmune's cutting-edge proprietary platform technologies that combine protein engineering with AI. This unique combination enables the rapid identification and engineering of stable, soluble, multi-specific TCRs (T cell receptors) for immune cell engagement in oncology and autoimmune diseases. Enjoy an insightful noon of pitches, networking and a delicious lunch from 12:00 – 13:15! 👉Please register right over here by latest February 5th and spread the word to your colleagues, partners and friends: https://lnkd.in/erGD4c6e Karin Crisanto Carine Moya Franziska Dornblut #innovation #startups #pitching #biotech #healthcare

There was “a really positive mindset” at this year’s JPMorgan Chase & Co. Annual Healthcare Conference, our CEO Lars Nieba told Labiotech.eu “Compared to last year, it was like night and day. We are clearly coming out of the dark, and now we are seeing the sun rising,” he said. Engimmune experienced “a lot of interest in our innovative AI-based soluble TCR therapeutics platform, which is generating precision medicines for oncology and auto-immune diseases” he said. Read Lars’ full comments in Roohi M.'s article here: https://lnkd.in/eZRPJT7p

Our CEO Lars Nieba presenting Engimmune's soluble TCR oncology pipeline and AI-guided protein engineering toolbox at Biotech Showcase 2024. Reach out to us if you'd like to learn more - we'll be in San Francisco all week!